Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10922111 | 0.79 | QDPR (0.40) | CHRNB2CHRNA4 | |
| SCHEMBL1898647 | 0.73 | — | — | |
| SCHEMBL3168555 | 0.73 | QDPR (0.32) | — | |
| Succinic Acid SCHEMBL2849113 | 0.71 | USP5 (0.33) | — | |
| SCHEMBL8872933 | 0.69 | — | — | |
| SCHEMBL10534322 | 0.67 | MBTD1 (0.39) | CHRNB2CHRNA4 | |
| SCHEMBL4824901 | 0.67 | PRMT3 (0.36) | — | |
| SCHEMBL11098492 | 0.66 | POLB (0.32) | — | |
| SCHEMBL10697906 | 0.65 | QDPR (0.34) | — | |
| SCHEMBL6512480 | 0.64 | LMNA (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011038469-A1 | SUPPRESSIVE AGENTS | PRINCE HENRY'S INSTITUTE OF MEDICAL RESEARCH (AU) | 2011-04-07 | — | — | WO | disclosed |
| WO-2010088729-A1 | COMPOSITIONS AND USES THEREFOR | UNIVERSITY OF TASMANIA THROUGH THE MENZIES RESEARCH INSTITUTE (AU) | 2010-08-12 | — | — | WO | disclosed |
| WO-2010022444-A1 | METHODS AND AGENTS FOR MODULATING KINASE SIGNALLING PATHWAYS THROUGH MODULATION OF MIXED-LINEAGE KINASE DOMAIN-LIKE PROTEIN (MLKL) | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2010-03-04 | — | — | WO | disclosed |
| US-20090215669-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETES | DIA-B TECH LIMITED (AU) | 2009-08-27 | — | — | US | disclosed |
| WO-2009021289-A1 | POTASSIUM CHANNEL INHIBITORS | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2009-02-19 | — | — | WO | disclosed |
| CN-101365470-A | Compositions and methods for treating diabetes | DIA B TECH LTD (AU) | 2009-02-11 | — | — | CN | disclosed |
| EP-1962882-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETES | Dia-B Tech Limited (AU) | 2008-09-03 | — | — | EP | disclosed |
| WO-2008025069-A1 | METHODS OF MODULATING CELLULAR ACTIVITY AND COMPOSITIONS THEREFOR | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2008-03-06 | — | — | WO | disclosed |
| US-20070197430-A1 | Conjugates And Therapeutic Uses Thereof | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2007-08-23 | — | — | US | disclosed |
| WO-2007059569-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETES | DIA-B TECH LIMITED (AU) | 2007-05-31 | — | — | WO | disclosed |
| EP-1781689-A1 | CONJUGATES AND THERAPEUTIC USES THEREOF | The Walter and Eliza Hall Institute of Medical Research (AU) | 2007-05-09 | — | — | EP | disclosed |
| WO-2007025332-A1 | A PEPTIDE AND ZINC ION COMPOSITION FOR TREATING DIABETES AND ENHANCING IMMUNE FUNCTION | DIA-B TECH LIMITED (AU) | 2007-03-08 | — | — | WO | disclosed |
| US-20070032417-A1 | Peptides and therapeutic uses thereof | WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2007-02-08 | — | — | US | disclosed |
| WO-2006000034-A1 | CONJUGATES AND THERAPEUTIC USES THEREOF | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2006-01-05 | — | — | WO | disclosed |
| WO-2004058804-A1 | PEPTIDES AND THERAPEUTIC USES THEREOF | WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032417-A1 | Peptides and therapeutic uses thereof | BCL2, BAX, BCL2L13 | CHRNB2 4409/4885CHRNA4 4845/4885 |
| US-20070197430-A1 | Conjugates And Therapeutic Uses Thereof | BCL2, BAX, BAD | CHRNB2 3895/4885CHRNA4 4763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.